HNRNPH2 Antibody

What is HNRNPH2 and why is it significant in research?

HNRNPH2 (Heterogeneous Nuclear Ribonucleoprotein H2) is a component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complexes that process pre-mRNAs before they become functional, translatable mRNAs in the cytoplasm. It binds poly(RG) sequences and plays crucial roles in RNA processing . The protein has gained significant research interest due to its association with an X-linked neurodevelopmental disorder characterized by developmental delay, motor function deficits, and seizures . Research into HNRNPH2 is particularly valuable for understanding RNA processing mechanisms and specific neurodevelopmental conditions.

What types of HNRNPH2 antibodies are available for research applications?

Multiple types of HNRNPH2 antibodies are available for research, primarily differing in their clonality:

Both types have been validated against human, mouse, and rat samples, making them suitable for comparative studies across these species .

How do I properly store and handle HNRNPH2 antibodies to maintain their activity?

For optimal results with HNRNPH2 antibodies:

• Store at -20°C as indicated by manufacturers

• Most preparations contain glycerol as a cryoprotectant

• Avoid repeated freeze-thaw cycles by aliquoting upon receipt

• Working dilutions should be prepared fresh and stored at 4°C for short periods only (1-2 weeks)

• Follow manufacturer's specific guidelines for each antibody preparation, as buffer compositions may vary

• Stability is typically guaranteed for 12 months from date of receipt when properly stored

How do I validate the specificity of an HNRNPH2 antibody for my research?

A comprehensive validation approach should include:

• Western blot validation with positive and negative controls:

  • Use siRNA knockdown models as demonstrated in validation studies

  • Test recombinant proteins of related family members (HNRNPH1, HNRNPF, HNRNPH3) to assess cross-reactivity

  • Examine multiple tissue/cell types known to express HNRNPH2

• Cross-validation with multiple antibodies:

  • Compare results using different antibody clones targeting different epitopes

  • Verify subcellular localization (primarily nuclear for wild-type HNRNPH2)

• Recombinant expression:

  • Express tagged versions of HNRNPH2 and confirm antibody detection

  • Include mutant versions (R206W, R206Q, P209L) if studying disorder-related variants

The ab181171 antibody has been validated through siRNA knockdown, showing significant reduction in signal in HNRNPH2-targeted siRNA samples compared to scrambled siRNA controls, confirming specificity .

What are the optimal dilutions and applications for HNRNPH2 antibodies?

Based on validated research applications:

For optimal results in immunohistochemistry applications, heat-mediated antigen retrieval using Tris-EDTA buffer (pH 9.0) is recommended, with overnight incubation at 4°C .

How can I distinguish between HNRNPH2 and its close paralogs (HNRNPH1, HNRNPF, HNRNPH3) in my experiments?

This is a challenging issue due to high sequence homology between these proteins:

• Antibody selection:

  • Choose antibodies validated against all family members (e.g., ab181171 which shows slight cross-reactivity with HNRNPH1 but not with HNRNPF and HNRNPH3)

  • Target unique regions of HNRNPH2 where sequence diverges from paralogs

• Experimental approaches:

  • Western blotting: Resolve proteins carefully as they have similar molecular weights

  • Use knockout/knockdown validation to confirm specificity

  • Consider isoform-specific PCR as complementary approach

  • When possible, combine mass spectrometry identification with immunoprecipitation

• Data analysis:

  • Always note potential cross-reactivity in publications

  • When analyzing cellular localization, consider that all family members are primarily nuclear

How can HNRNPH2 antibodies be utilized to study disease-associated mutations?

Research on HNRNPH2 mutations requires specialized approaches:

• Mutant protein detection:

  • Express tagged wild-type and mutant (R206W, R206Q, P209L) HNRNPH2

  • Use antibodies that don't target the mutation regions

  • Compare subcellular distribution patterns (WT is primarily nuclear; mutants show nuclear and cytoplasmic localization)

• Functional studies:

  • Immunoprecipitation to study altered protein interactions (e.g., reduced interaction with Kapβ2)

  • Co-localization studies with stress granule markers (e.g., eIF3η) under oxidative stress conditions

  • GST-pulldown assays to quantify binding efficiency differences

• Protocol modifications:

  • For stress granule visualization: Treat cells with 0.5 mM NaAsO₂ to induce stress granules before fixation

  • For nuclear-cytoplasmic fractionation: Use low detergent concentrations to preserve nuclear integrity

What methodological considerations are important when studying HNRNPH2 localization changes under stress conditions?

Based on recent research :

• Oxidative stress experimental design:

  • Baseline imaging: Capture normal localization in unstressed cells

  • Treatment: 0.5 mM NaAsO₂ for stress granule induction

  • Timing: Monitor time-dependent relocalization

  • Co-staining: Use eIF3η as stress granule marker

• Quantification approaches:

  • Nuclear/cytoplasmic ratio calculation

  • Co-localization analysis with stress granule markers

  • Time-course documentation of relocalization

• Technical considerations:

  • Use gentle fixation to preserve stress granules (4% PFA recommended)

  • Employ confocal microscopy for precise localization assessment

  • Include multiple stress conditions (heat shock, hypoxia) for comprehensive analysis

  • Always include wild-type HNRNPH2 as control alongside mutants

How can I design experiments to investigate the interaction between HNRNPH2 and nuclear import receptor Kapβ2?

Based on documented methodologies :

• GST-pulldown approach:

  • Create GST-tagged constructs of HNRNPH2 PY-NLS region (aa 179-215)

  • Express and purify constructs from bacterial systems

  • Perform pulldown with recombinant Kapβ2

  • Use M9M peptide as positive control for binding site specificity

• Immunoprecipitation method:

  • Express full-length HNRNPH2 (WT and mutants) in mammalian cells

  • Perform co-immunoprecipitation with Kapβ2

  • Quantify interaction efficiency through western blot analysis

  • Compare binding reduction between PY-NLS mutants (R206W/Q/G, P209L, Y210C) and non-PY-NLS mutants (D340V)

• Quantification and controls:

  • Always include wild-type as positive control

  • Use non-PY-NLS mutant (D340V) as reference point for interaction reduction

  • Quantify results across multiple experimental replicates

  • Report binding efficiency as percentage relative to wild-type

What are common causes of inconsistent results when using HNRNPH2 antibodies, and how can they be addressed?

Common challenges and solutions include:

• Variable western blot results:

  • Problem: Inconsistent band patterns or intensities

  • Solutions:

    • Optimize protein extraction methods (nuclear proteins require efficient extraction)

    • Careful sample handling to prevent protein degradation

    • Consistent loading and transfer conditions

    • Standardize blocking conditions (5% NFDM/TBST recommended)

• Poor signal in immunohistochemistry:

  • Problem: Weak or absent nuclear staining

  • Solutions:

    • Ensure proper antigen retrieval (Tris-EDTA buffer pH 9.0 is optimal)

    • Extended primary antibody incubation (overnight at 4°C)

    • Freshly prepared detection reagents

    • Validate tissue fixation protocols

• Nonspecific background:

  • Problem: High background obscuring specific signal

  • Solutions:

    • Increased blocking time or concentration

    • More stringent washing steps

    • Antibody titration to determine optimal concentration

    • Pre-adsorption of secondary antibodies

How do I interpret unexpected cellular localization patterns of HNRNPH2 in my experiments?

When encountering unexpected localization patterns:

• Cytoplasmic localization in wild-type HNRNPH2:

  • Expected pattern: Almost exclusively nuclear

  • Possible explanations:

    • Cell stress conditions (check for inadvertent stress during processing)

    • Cell cycle stage variations (synchronized cultures recommended for definitive studies)

    • Antibody cross-reactivity with cytoplasmic proteins

    • Fixation artifacts altering nuclear envelope integrity

• Verification approaches:

  • Compare multiple antibodies targeting different epitopes

  • Validate with tagged recombinant expression

  • Perform careful subcellular fractionation

  • Co-stain with nuclear and cytoplasmic markers

• Disease-relevant interpretation:

  • Certain mutations (R206W, R206Q, P209L) cause increased cytoplasmic localization

  • Stress conditions (0.5 mM NaAsO₂) enhance cytoplasmic accumulation of mutant proteins

  • Correlation between cytoplasmic accumulation and dysfunction of nuclear import via Kapβ2

What are the methodological considerations for quantifying changes in HNRNPH2 protein expression levels in disease models?

For rigorous quantification:

• Western blot quantification:

  • Normalize to multiple housekeeping controls

  • Use linear range detection methods

  • Compare multiple antibodies targeting different regions

  • Consider nuclear vs. whole cell extracts separately

• Immunohistochemistry quantification:

  • Employ digital image analysis for nuclear intensity measurement

  • Use consistent exposure and acquisition parameters

  • Include calibration standards

  • Analyze multiple fields and samples to account for heterogeneity

• Advanced approaches:

  • Consider mass spectrometry-based quantification for absolute measurements

  • RNA-protein correlation studies (qPCR with protein levels)

  • Single-cell analysis techniques to detect population heterogeneity

  • Time-course studies to capture dynamic changes

How can HNRNPH2 antibodies be utilized in research on X-linked neurodevelopmental disorders?

Based on recent research findings :

• Patient-derived cell studies:

  • Compare HNRNPH2 localization in patient vs. control cells

  • Analyze RNA processing alterations in patient samples

  • Test pharmacological interventions to correct mislocalization

• Animal model validation:

  • Confirm antibody cross-reactivity with model species protein

  • Compare expression patterns across developmental stages

  • Correlate protein expression/localization with behavioral phenotypes

• Mechanistic investigations:

  • Study PY-NLS dependent nuclear import in patient-derived cells

  • Investigate stress granule dynamics and RNA processing

  • Examine potential therapies targeting nuclear import or RNA processing

• Methodological approaches:

  • Immunofluorescence to track subcellular localization changes

  • Co-immunoprecipitation to identify altered protein interactions

  • RNA-immunoprecipitation to define changes in RNA targets

What experimental design considerations are important when investigating HNRNPH2 binding to poly(RG) sequences?

For studying the RNA-binding functions:

• Binding assay approaches:

  • RNA-immunoprecipitation with HNRNPH2 antibodies

  • Electrophoretic mobility shift assays with recombinant protein

  • CLIP-seq methodologies for genome-wide binding analysis

  • Compare wild-type versus mutant binding efficiency

• Critical controls:

  • Include related hnRNP proteins (HNRNPH1, HNRNPF) as comparators

  • Use multiple RNA substrates (poly(RG) and non-RG controls)

  • Test binding under different ionic strength conditions

  • Compare nuclear and cytoplasmic fractions separately

• Analytical considerations:

  • Quantify binding affinity through multiple approaches

  • Consider cooperative binding effects

  • Evaluate competition with other RNA-binding proteins

  • Correlate binding changes with functional RNA processing outcomes

How might recent findings on HNRNPH2 nuclear import mechanisms inform therapeutic approaches for associated disorders?

Based on mechanistic insights :

• Potential therapeutic targets:

  • Nuclear import pathway enhancement

  • Targeting Kapβ2-mediated transport specifically

  • Modulating stress granule dynamics

  • RNA processing compensation strategies

• Experimental therapeutic approaches:

  • Small molecules targeting PY-NLS/Kapβ2 interaction

  • Gene therapy to express optimized nuclear localization signals

  • Antisense oligonucleotides to modulate RNA processing

  • Stress pathway modulators to prevent cytoplasmic accumulation

• Model systems for therapeutic testing:

  • Patient-derived iPSCs differentiated to neurons

  • Mouse models with equivalent HNRNPH2 mutations

  • Cell lines expressing mutant proteins

  • Ex vivo brain slice cultures

• Outcome measures:

  • Nuclear/cytoplasmic distribution quantification

  • RNA processing fidelity assessment

  • Stress granule dynamics under various conditions

  • Downstream gene expression normalization